HIV and co-infections

CC Chang; M Crane; J Zhou; M Mina; JJ Post; BA Cameron; AR Lloyd; A Jaworowski; MA French; SR Lewin

Journal article

HIV and co-infections

CC Chang, M Crane, J Zhou, M Mina, JJ Post, BA Cameron, AR Lloyd, A Jaworowski, MA French, SR Lewin

Immunological Reviews | Published : 2013

DOI: 10.1111/imr.12063

Abstract

Summary: Despite significant reductions in morbidity and mortality secondary to availability of effective combination anti-retroviral therapy (cART), human immunodeficiency virus (HIV) infection still accounts for 1.5 million deaths annually. The majority of deaths occur in sub-Saharan Africa where rates of opportunistic co-infections are disproportionately high. In this review, we discuss the immunopathogenesis of five common infections that cause significant morbidity in HIV-infected patients globally. These include co-infection with Mycobacterium tuberculosis, Cryptococcus neoformans, hepatitis B virus, hepatitis C virus, and Plasmodium falciparum. Specifically, we review the natural hist..

View full abstract

University of Melbourne Researchers

Sharon Lewin Author

Related Projects (3)

IMPROVED HEALTH OUTCOMES FOR PEOPLE LIVING WITH HIV

Despite the success of antiviral therapy for HIV infection, HIV cannot be cured and treatment is life long. In addition, there are complicat..

How white blood cells clear malaria infection, and how this alters the immune response

Macrophage white blood cells clear malaria infected cells by eating them, by three routes- by recognising ANTIBODIES or COMPLEMENT on the ce..

HIV & HCV Vaccines and Immunopathogenesis

The development of vaccines and better treatments for HIV-AIDS and Hepatitis C are urgent global health priorities. This Program will undert..

Grants

Awarded by National Institute of Allergy and Infectious Diseases

Funding Acknowledgements

C. C. C. was supported by the Australian Commonwealth Government for the Australian Postgraduate Award 2009, Australian NHMRC (National Health and Medical Research Council) Postgraduate Scholarship 2010-2012 and Pfizer Neuroscience Research Grant. M. C. is supported by a Mathilde Krim Biomedical Fellowship from the American Foundation for AIDS Research; M. M. is supported by an Australian Postgraduate Association scholarship. A. R. L. is an NHMRC Practitioner Fellow (1043607). A. J. is supported by an NHMRC project grant 628611. M. A. F. is supported by NHMRC grant 510448 and the Reach Initiative (Research and Education in HIV/AIDS for Resource Poor Countries). S. R. L. is a NHMRC practitioner fellow (1042654) and is supported by the National Institutes of Health (NIH; U19 AI096109). The authors have no conflicts of interest to declare.